Welcome to our dedicated page for Matinas Biopharm SEC filings (Ticker: MTNB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Matinas BioPharma Holdings, Inc. (MTNB) SEC filings page on Stock Titan brings together the company’s public regulatory disclosures from the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer listed on the NYSE American, Matinas uses filings such as Forms 10-K, 10-Q, and 8-K to report on its business, financial condition, and material corporate events related to its lipid nanocrystal (LNC) platform and lead antifungal candidate MAT2203.
Annual reports on Form 10-K typically provide a detailed description of Matinas’ business, including the development status of MAT2203 as an oral amphotericin B for invasive fungal infections, the broader LNC platform for small molecules and small oligonucleotides, key risk factors, and discussion of liquidity and capital resources. Quarterly reports on Form 10-Q update investors on operating results, research and development spending, and balance sheet items such as cash, cash equivalents, and marketable securities, which are important for a company funding clinical trials and preclinical work.
Current reports on Form 8-K are particularly relevant for tracking near-term changes at Matinas. Recent 8-Ks have disclosed matters such as amendments to the Chief Executive Officer’s employment agreement and retention bonus tied to a potential Change in Control, board and committee appointments and resignations, stockholder approvals of an equity incentive plan and increases in authorized shares, warrant exchange agreements, and a NYSE American noncompliance notice related to the timing of the annual meeting. These filings help clarify how governance, capital structure, and strategic alternatives may affect shareholders.
Investors can also review equity and compensation-related filings, including documents describing the 2025 Equity Incentive Plan and amendments to the certificate of incorporation to increase authorized common stock. On Stock Titan, AI-powered tools summarize lengthy Matinas filings, highlight key terms, and make it easier to locate information on topics such as MAT2203 development plans, LNC platform risks, and corporate transactions, while direct links to Form 4 and other ownership filings allow users to monitor insider and significant holder activity reported to the SEC.
Highbridge Capital Management reported beneficial ownership of 466,667 shares of Matinas BioPharma Holdings common stock, representing 8.4% of the outstanding class based on 5,086,985 shares outstanding. The reported shares are issuable upon exercise of warrants held by Highbridge Funds and are held on behalf of those funds, with Highbridge Tactical Credit Master Fund, L.P. identified as having rights to more than 5% of the class. The filing clarifies that these securities were acquired and are held in the ordinary course of business and not for the purpose of changing control.
Matinas BioPharma Holdings, Inc. (MTNB) filed an 8-K (Item 5.03) reporting a Certificate of Amendment that doubles its authorized common stock to 500 million shares, up from 250 million. The amendment was approved at the 23 Jun 2025 annual meeting and became effective upon filing with Delaware on 6 Aug 2025.
No shares were issued and no financial statements accompanied the filing. The increased authorization gives the company added flexibility to raise capital, fund strategic transactions or expand equity-based compensation plans. However, future issuances could dilute existing shareholders and pressure per-share metrics. Investors should track subsequent financings or option grants that may utilize the newly authorized shares.
Matinas BioPharma Holdings, Inc. (MTNB) has filed a Form S-8 with the SEC on 23 June 2025 to register securities issuable under its new 2025 Equity Incentive Plan. The filing designates the company as a non-accelerated filer and smaller reporting company. Plan information required by Section 10(a) is omitted from this registration statement and will be provided directly to eligible service providers in accordance with Rule 428.
The company incorporates by reference its recent SEC filings, including: (a) the Form 10-K for the year ended 31 December 2024 (filed 15 April 2025); (b) the Form 10-Q for the quarter ended 31 March 2025 (filed 15 May 2025); (c) eleven Form 8-K filings between 10 January and 23 June 2025; and (d) the description of its common stock contained in its Form 8-A (as updated).
Standard undertakings are provided to file post-effective amendments for material changes, and the company reiterates Delaware General Corporation Law (DGCL) indemnification provisions for directors and officers. Exhibits will be listed in the Exhibit Index (not included in the excerpt). Jerome D. Jabbour, Chief Executive Officer, is named as the agent for service, with Lowenstein Sandler LLP serving as counsel.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) filed an 8-K summarizing the results of its 23 June 2025 Annual Meeting. Key outcomes were:
- 2025 Equity Incentive Plan approved – 5.39 m votes for, 0.28 m against, 0.02 m abstain; 1.81 m broker non-votes. The plan is now effective and replaces/expands prior equity programs.
- Reverse stock split authority – Shareholders authorized the Board to effect up to two reverse splits within a 1-for-2 to 1-for-199 ratio over two years (6.94 m for, 0.54 m against).
- Authorized share increase – The Charter will be amended to raise common shares from 250 m to 500 m (6.91 m for, 0.57 m against).
- Director slate re-elected – All five nominees received ~5.65 m votes each; no nominee received more than 1% withholds.
- Say-on-pay approved – Executive compensation supported by 95.3% of votes cast.
The additional share authorization and broad reverse-split range give the Board considerable flexibility to manage listing compliance, future financings and potential M&A, but could also result in material dilution or a sharply reduced share count if a high-ratio split is executed. The 2025 Plan increases equity compensation capacity, aligning management incentives but adding potential overhang. No immediate financial impact was disclosed.